VistaGen Therapeutics, Inc. (VTGN) is an innovative biopharmaceutical company that is committed to developing and commercializing new generation medications to treat various diseases that impact the central nervous system. The company focuses on integrating human biology and genetic data to assist drug discovery, development, and commercialization. Located in South San Francisco, California, VistaGen has been advancing towards becoming a leading biotech company since its inception in 1998.
The primary focus of VistaGen Therapeutics is to develop novel treatments for mental health disorders such as depression, anxiety, and suicidal ideation. Its pipeline includes PH10, a rapid-onset treatment for major depressive disorder (MDD) which is currently in Phase 2 development. Another standout drug is AV-101, an oral NMDA (N-methyl D-aspartate) receptor antagonist, currently in Phase 2 development for major depressive disorder amongst other potential indications.
The company’s other in-progress medicinal treatment includes PH94B, a rapid-onset treatment for social anxiety disorder (SAD). VistaGen Therapeutics aims to create solutions that do not only treat the symptoms but also fixes the disorder at its root. Leveraging multiple technologies, the company focuses on using human stem cell technology to predict the success of their medication options and ensuring that they are safer and more effective.
One of the standout features of this biotech company is its drug rescue variants. The process of drug rescue intends to further the developmental progress of drug candidates that have not been successful in the past due to heart toxicity, despite potential therapeutic benefits. VistaGen’s cardiovascular liver cell (CvLi) technology platform has been created to potentially rescue and advance these drug candidates by using a unique type of stem cell-derived human heart cell to detect toxicity and predict potential heart-related side effects during the early stages of drug development.
The character, integrity, and intense focus of VistaGen Therapeutics, Inc. drive them to develop and learn continuously. Their mission is primarily focused on helping patients and healthcare providers by delivering innovative, patent-protected, and commercially competitive medicines with improvements over current treatments. With their promising pipeline and dedication to innovation and safety, Vistagen Therapeutics, Inc. holds a commanding position in the global biopharmaceutical field.